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Introduction
The introduction of biological therapies (BT) has improve
the management of patients with Juvenile Idiopathic
Arthritis (JIA) in terms of relive of symptoms, enhancing
the quality of live and reducing joint damage. Its pharma-
cological activity induces immunity transitory suppression
that supposes an increased risk of acquire infectious
diseases or a major severity of them. TB adverse events
registries have painted special attention to severe that
conditioned in bed stay at hospitals or mortality and most
of them are focused on adult cohorts. Paediatric BT
adverse events registries are significantly fewer compared
to adults and the recount of mild and moderate adverse
events (according to OMERACT-8 definitions), which are
fortunately highly frequent than others, have not properly
compared with healthy children.
Objectives
The purpose of this study is to determine the increase
of risk of develop a mild or moderate adverse event in
patients with JIA receiving BT compared to healthy
people.
Methods
We conducted a retrospective cohort study. Complete
medical records of patients with JIA treated with BT since
2002 in our unit were revised. Among this group
we included those patients who started BT before 16 years
old. Control cohort was composed by healthy subjects
same age and sex. Controls were obtained randomly from
two different primary care units related to our hospital
until complete three subjects for each case. The recount of
mild and moderate adverse events was performed since
starting BT in our cohort and at the same age in controls.
All recounts finalized when BT was stopped of when
subjects (patients or not) reached 16 years old or at
December 31th, 2012.
Results
Thirty patients were followed up during an average of 4.2
SD 1.8 years. Time of effective exposure to BT, excluding
periods of stop of prescription was 3.1 SD 1.5 years.
Healthy subjects were followed up an average of 4.8 SD
1.4 years. Incidence of mild adverse effects was 1.9 cases/
patient/year in the BT group and 1.05 cases/subject/year
into the control group (p < 0.05) which represents a risk
increase of 80.9%. Incidence of moderate adverse events
was 1.56 cases/patient/year in the BT group and 1.26
cases/patient/year into the control group (p = 0.04) which
represents a risk increase of 23.8%.
Conclusion
OMERACT definition of mild adverse events makes dif-
ficult its complete registration into medical records and
it could underestimate its prevalence in healthy people
compared with patients with JIA receiving BT who
are under a close follow up. With this in mind we
believe that the most valuable result is the risk increase
of moderate adverse events due their need of medical
approach (by definition). Considering that moderate
adverse events are more frequent than severe ones, we
consider this study provides relevant information to
share with parents of patients who potentially will take
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BT. It is necessary a prospective follow up of major
cohorts and over longer periods of time to obtain
valuable information about risk increase among different
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